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Interleukin-3 (IL-3) is an activated T cell product that
bridges innate and adaptive immunity and contrib-
utes to several immunopathologies. Here, we report
the crystal structure of the IL-3 receptor a chain
(IL3Ra) in complex with the anti-leukemia antibody
CSL362 that reveals the N-terminal domain (NTD), a
domain also present in the granulocyte-macrophage
colony-stimulating factor (GM-CSF), IL-5, and IL-13
receptors, adopting unique ‘‘open’’ and classical
‘‘closed’’ conformations. Although extensive muta-
tional analyses of the NTD epitope of CSL362 show
minor overlap with the IL-3 binding site, CSL362
only inhibits IL-3 binding to the closed conformation,
indicating alternative mechanisms for blocking IL-3
signaling. Significantly, whereas ‘‘open-like’’ IL3Ra
mutants can simultaneously bind IL-3 and CSL362,
CSL362 still prevents the assembly of a higher-order
IL-3 receptor-signaling complex. The discovery of
open forms of cytokine receptors provides the
framework for development of potent antibodies
that can achieve a ‘‘double hit’’ cytokine receptor
blockade.
INTRODUCTION
Interleukin 3 (IL-3) is a cytokine produced largely by antigen-acti-
vated T cells that links immunity to the hemopoietic system and
plays a significant role in leukemia as well as several immunopa-
thologies (Hercus et al., 2013). Through actions on several cell
types, IL-3 contributes to allergic inflammation, autoimmune dis-
eases, and oncogenesis (Korpelainen et al., 1993; Broughton
et al., 2012). Importantly, leukemic stem cells from patients
with acute myeloid leukemia (AML) (Jordan et al., 2000) and410 Cell Reports 8, 410–419, July 24, 2014 ª2014 The Authorschronic myeloid leukemia (CML) (Nievergall et al., 2014) overex-
press the IL-3 receptor a chain (IL3Ra), and this is associated
with a poor prognosis in AML (Testa et al., 2002). Understanding
how the IL-3 receptor signals and designing strategies to opti-
mally target the IL-3 receptor has become a pressing need.
The IL-3 receptor belongs to the bc family of heterodimeric re-
ceptors that includes the granulocyte-macrophage colony-stim-
ulating factor (GM-CSF) and IL-5 receptors and is part of the type
I cytokine receptor superfamily. The bc family utilizes specific
subunits (a) that bind the cognate cytokine as well as the shared
subunit (bc) that is essential for signaling (Hercus et al., 1994). In
the GM-CSF receptor, a dodecamer assembly brings bc-associ-
ated JAK2 molecules on hexamer complexes into close prox-
imity to initiate receptor signaling (Hansen et al., 2008) with a
similar mechanism proposed for IL-3 and IL-5 receptor signaling
(Patino et al., 2011; Kusano et al., 2012; Broughton et al., 2012).
The IL3Ra N-terminal domain (NTD) allows optimal IL-3 bind-
ing but is not essential for IL-3 signaling (Barry et al., 1997; Chen
et al., 2009). Paradoxically, monoclonal antibody (mAb) 7G3 rec-
ognizes the IL3Ra NTD (Sun et al., 1996; Barry et al., 1997) and
completely blocks IL-3 binding and signaling. We recently
showed that mAb 7G3 eliminates engrafted human AML stem
cells in a mouse model of human AML (Jin et al., 2009). mAb
7G3, now humanized and designated as CSL362 (Busfield
et al., 2014), is entering clinical trials for the treatment of patients
with AML (ClinicalTrials.gov identifier: NCT01632852). We have
now used a Fab fragment of CSL362 to solve the structure of
IL3Ra and reveal the underlying mechanisms of CSL362-medi-
ated IL-3 receptor blockade. First, we observed IL3Ra NTD in
two distinct conformations, ‘‘open’’ and ‘‘closed,’’ suggesting
that the NTD ismobile andmaymodulate IL-3 signaling. Second,
CSL362 and IL-3 utilize functionally distinct binding sites on
IL3Ra, and using ‘‘open-like’’ IL3Ra mutants, we showed that
CSL362 can inhibit IL-3 signaling without inhibiting IL-3 binding.
Third, when combined with direct competition for IL-3 binding to
the closed IL3Ra, it is clear that CSL362 has dual mechanisms
leading to IL-3 receptor blockade. Finally, we generated a model
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Figure 1. Structure of the IL3Ra:CSL362 Fab
Complex
(A) Crystal structure of the IL3Ra:CSL362 binary
complex reveals two conformational states: open
and closed. IL3Ra in yellow, CSL362 heavy chain
in dark blue, CSL362 light chain in light blue, and
glycan molecules represented as pink sticks.
(B) View of the interface between IL3Ra NTD and
D2 in the open and closed complexes.Key features
are indicated, including the C76-C194 disulfide
bond and the distance between S74 and D196.
(C and D) ‘‘Side on’’ (C) and ‘‘top down’’ (D; when
looking down onto the membrane surface) views
of related cytokine receptors, IL5Ra (PDB ID:
3QT2; Patino et al., 2011), IL13Ra1 (PDB ID:
3BPO; LaPorte et al., 2008), and IL13Ra2 (PDB
ID: 3LB6; Lupardus et al., 2010). Receptors are
aligned via their D2-D3 domains to the closed form
of IL3Ra and colored yellow with NTD domains red
and cytokines gray.
(E) Comparison of the NTD-D2 interface for IL5Ra
(orange), IL13Ra1 (pink), and IL13Ra2 (green);
same alignment as in (C) and (D) and same view as
for IL3Ra in (B). In IL5Ra, D208 hydrogen bonds to
the amide nitrogen of both L70 and H71.
See also Figures S1–S4 and Table S1.of the functional IL-3 receptor based on these structural, func-
tional, and homology studies, which support the requirement
of a higher-order assembly for IL-3 receptor signaling. These re-
sults have important implications for understanding cytokine re-
ceptor signaling and for guiding the development of novel and
potent anti-cytokine-receptor antibodies.
RESULTS
The Structure of the IL3Ra:CSL362 Complex Reveals
Open and Closed Conformations of IL3Ra
Soluble IL3Ra (sIL3Ra) was bound to the Fab fragment of
CSL362 and the crystal structure of the binary complex deter-
mined (Figure S1; Table S1). For complete crystallization details,Cell Reports 8, 410–see Broughton et al. (2014). Two indepen-
dent forms of the binary complex were
observed in the asymmetric unit of the
unit cell, an open and a closed form,
each of which comprise a sIL3Ra mole-
cule and a CSL362 Fab (Figure 1A). In
both forms, CSL362 Fab binds to the
NTD of IL3Ra, consistent with cell binding
studies (Figure S2).
The IL3Ra structure reveals a well-
defined immunoglobulin-like NTD that
adopts a typical fibronectin type III (FnIII)
fold followed by two more FnIII domains
(D2 and D3) that form the cytokine recep-
tor module (CRM) that is typical for this
class of receptors (Broughton et al.,
2012). The major difference between the
two complexes is the angle between theNTD and D2, which differs by 40 (Figures 1A and S3A; see
theSupplemental Results). Theposition of theNTD is constrained
by the disulfide bond between C76 (NTD) and C194 (D2), a
hydrogen bond between S74 (NTD) and D196 (D2), and van der
Waals (vdW) interactions between A72 (NTD) and F198 (D2;
Figure 1B). Although it is possible that the two IL3Ra conforma-
tions are a result of crystal packing, the biological data presented
below suggest a functional purpose for the flexibility of the NTD-
D2 linker region that results in the receptor adopting both confor-
mations and possibly a dynamic continuum between them.
Unique and Conserved Structural Features of IL3Ra
The ligand-free IL3Ra structures were compared to structures
for other bc receptors, including two structures of IL5Ra in419, July 24, 2014 ª2014 The Authors 411
complex with IL-5 (Protein Data Bank [PDB] IDs: 3QT2 and 3VA2;
Patino et al., 2011; Kusano et al., 2012), and our partial structure
of GMRa in the GM-CSF receptor ternary complex (PDB ID:
3CXE; Hansen et al., 2008). Whereas GMRa structural data are
largely restricted to D3, the closed conformation of IL3Ra clearly
resembles the ‘‘wrench-like’’ fold observed in IL5Ra bound to
IL-5 (Figure 1C). The two IL5Ra binary complexes observed in
the asymmetric unit of 3QT2 and the one in 3VA2 are very similar
(Ca root-mean-square-deviation [rmsd] = 0.5 A˚); hence all
comparisons with IL3Ra have been carried out using 3QT2.
The CRMs of IL3Ra and IL5Ra superimpose closely with the
biggest difference being a lengthy loop region in IL5Ra (E120–
Y129) that is proximal to the D2-D3 linker, protruding outward
toward the cytokine-binding interface. The core b sheet structure
of the NTDs is largely maintained between IL3Ra and IL5Ra (Ca
rmsd = 1.6 A˚); however, in IL5Ra, the four-stranded b sheet at
the distal tip from the CRM twists toward the cytokine and the
loops in this region are considerably longer (Figure S4A).
A 3D structural comparison of IL3Ra bound to CSL362 using
the PDB eFold server (http://www.ebi.ac.uk/msd-srv/ssm) re-
vealed similarity with other type I cytokine receptors. Outside
the bc family, the closed conformation of IL3Ra has the strongest
similarity with the IL-13 receptors, IL13Ra1 and IL13Ra2, that
bind IL-13 in a pincer-like grip between the NTD and the CRM
(Figures 1C and 1D; PDB IDs: 3BPO [LaPorte et al., 2008] and
3LB6 [Lupardus et al., 2010]). The core b sheet structure of
the IL3Ra NTD overlays well with the NTDs of IL13Ra1 and
IL13Ra2 (Ca rmsd = 1.6 A˚ for both); however, loop regions at
the CRM distal tip of the NTD in IL13Ra1/IL13Ra2 are lengthy
compared to the relatively compact loops of IL3Ra. Although
the NTD-D2 and D2-D3 elbow angles are similar between the
closed IL3Ra conformation, IL5Ra, IL13Ra1, and IL13Ra2, the
IL3Ra NTD is twisted away from the D2-D3 axis by 30
compared to the other receptors so that it is not sitting directly
above D2 (Figure 1D). See the Supplemental Results for addi-
tional comparisons.
Residues located at theNTD-D2 interface for IL3Ra (Figure 1B)
and IL5Ra (Figure 1E) show some conservation: e.g., IL5Ra
D208 (analogous to IL3Ra D196) hydrogen bonds to L70 and
H71 (NTD) whereas V67 (NTD) makes vdW interactions with
W190 and L210 (D2). There is little sequence identity between
IL3Ra and IL13Ra1/IL13Ra2 in the NTD-D2 interface; however,
a number of hydrogen bonds and vdW interactions may serve
a similar role in orientating the NTD (Figures 1B and 1E).
CSL362 Binds to a 15 Amino Acid Epitope in the
IL3Ra NTD
The CDR loops from CSL362 interact with strand D and portions
of the BC, DE, and FG loops of IL3Ra NTD (Figures 2A, S1A, and
S1B; see the Supplemental Results) and the CDR interface with
IL3Ra in both open and closed conformations are essentially
identical (Ca rmsd = 0.5 A˚; Figure 2B). The interacting residues
are shown in Figures 2C and 2D. Although closely associated
with the CSL362 epitope, the N-linked glycosylation at N80 of
IL3Ra is not required for CSL362 binding (see the Supplemental
Results; Figures S3C–S3E).
All CDR loops of CSL362 interact with the IL3Ra NTD, except
for the light-chain CDR2 loop, and are detailed in Table S2. The412 Cell Reports 8, 410–419, July 24, 2014 ª2014 The Authorsheavy (H) and light (L) chains of CSL362 form ten hydrogen
bonds and three salt bridges with IL3Ra (Figure 2D; Table S2).
The side-chain hydroxyl of CDR1H Tyr33H forms hydrogen
bonds between the amide nitrogen atom of V85 and the carbonyl
of F90. CDR2H Asp50H forms a salt bridge with the guanidine
moiety of R84, and two salt bridges are formed between
CDR3H Arg103 and both D49 and E51. CDR3L residues
Tyr98L, Ser99L, Tyr100L, and Tyr102L hydrogen bond to S59
through both main-chain and side-chain interactions whereas
two hydrogen bonds are formed between the side chains of
Tyr102L and E51 and R84. CDR3L residues Tyr98L, Ser99L,
and Tyr100L pack against the main chain of residues P61,
M60, S59, Y58, D57, and A56. These interactions define the
structural epitope of CSL362 binding to IL3Ra and are consistent
with the CSL362-interacting footprint determined in solution
using hydrogen/deuterium exchange (see the Supplemental
Results).
Functional Characterization of the CSL362 Epitope on
the IL3Ra NTD
To define the productive interactions in the CSL362 epitope, we
assessed the binding of mAb 7G3 (from which CSL362 was
derived) to a panel of IL3Ra mutants by flow cytometry. This
analysis identified E51 and S59 as key determinants of 7G3 bind-
ing as well as revealing a role for an adjacent residue, P88 (Fig-
ure 2E). The interactions were quantified by saturation-binding
analysis of radioiodinated CSL362 to IL3Ra mutants. Mutation
of E51 and R84 abolished CSL362 binding whereas mutation
of Y58, S59, P61, and P88 reduced CSL362 binding (Table
S3). Surface plasmon resonance (SPR) analysis of CSL362 bind-
ing to sIL3Ra mutants also identified E51 as a critical determi-
nant whereas mutation of D49, Y58, S59, and P61 reduced
CSL362 binding (Table S3).
Identification and Characterization of the IL-3 Binding
Site in IL3Ra
To explore the mechanism of action for CSL362, we investigated
the location of the IL-3 binding site in IL3Ra. We constructed
models of the IL-3:IL3Ra binary complex based on (1) the open
and closed conformations of IL3Ra (Figure 1A), (2) published
mutagenesis data (Broughton et al., 2012), and (3) automated
cytokine-receptor docking (model details in Supplemental Re-
sults). In the open model, IL-3 can adopt multiple orientations,
whereas in the closed model, IL3Ra wraps around the cytokine
(Figure 3A), reminiscent of the IL5Ra and IL13Ra1/IL13Ra2 inter-
actions with cytokine (Figures 1C, 1D, and S4A). Superimposing
the bound CSL362 Fab on these models indicates that CSL362
and IL-3 are potentially able to bind simultaneously to IL3Ra in
the open model, whereas in the closed model, CSL362 overlaps
the docked IL-3 (Figure 3B). The closed IL-3:IL3Ra binary model
is very similar to the IL-5:IL5Ra binary complex (Figure S4A) with
the four a helices of IL-3 overlapping with helices A, B, C, and D’
in IL-5 (Patino et al., 2011; Kusano et al., 2012).
The binding of cytokine to its a subunit was first defined for the
two domain growth hormone receptors as site 1 (de Vos et al.,
1992). Classical site 1 interactions are predicted to occur be-
tween helices A, A’, and D of IL-3 and the ‘‘elbow’’ region be-
tween D2 and D3 of IL3Ra. This is site 1a in our model (Figures
Figure 2. The CSL362 Epitope on IL3Ra
(A) Cartoon representation of the interaction interface between IL3Ra and CSL362, colored as in Figure 1. CSL362-interacting loops and b strands are labeled.
(B) Overlay of the Ca trace of the IL3Ra NTD:CSL362 interface region from the open (yellow) and closed (blue) complexes.
(C) Surface representation of CSL362 showing the IL3Ra footprint on the heavy chain (dark blue) and the light chain (light blue) as well as the IL3Ra N80 glycan
contact (pink).
(D) Semitransparent surface view of IL3Ra with residues that interact with CSL362 colored red and the N80-linked glycan in pink. Detailed residue interactions
between CSL362 and IL3Ra are highlighted.
(E) Mapping of the CSL362 functional epitope by alanine (Ala) or evolutionary conserved (EC) mutation of IL3Ra residues 20–100 and measuring 7G3 binding by
flow cytometry.
Relative 7G3 binding, normalized for protein expression using 9F5 (A) or 107D2 (B) binding, is reported as 75%–100% (open squares), 50%–74% (pink
squares), 25%–49% (red squares), and 0%–24% (maroon squares). Data are shown from a representative experiment (n = 3). See also Figures S2–S4 and
Tables S2 and S3.3A, 3C, and 3D) whereas nonclassical contacts between IL-3
and the NTD of IL3Ra are distinguished as site 1b (Figures
3A, 3C, and 3D; details are provided in the Supplemental
Results; Table S4). IL-5 and IL-13 interact with their respective
a subunits in a similar manner (Figures 1C, 1D, and S4A) with
site 1a interactions located in similar regions, but not conserved.For site 1b, vdW interactions dominate for IL3Ra whereas
hydrogen bonds and polar interactions dominate for IL5Ra.
The IL13Ra1/IL13Ra2 site 1b interactions are comprised of
hydrogen bonds between cytokine and receptor, similar to
IL5Ra, and vdW interactions between cytokine and receptor,
similar to IL3Ra.Cell Reports 8, 410–419, July 24, 2014 ª2014 The Authors 413
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Figure 3. Molecular Modeling of IL-3 Bound to IL3Ra
(A) Docking of IL-3 to the open and closed conformations of IL3Ra colored as in Figure 1. The location of the NTD, D2, D3, and site 1 are indicated, and the IL-3 a
helices are labeled.
(B) Overlay of the open and closed IL-3 binary complex models on the respective open and closed IL3Ra:CSL362 crystal complexes with proteins depicted as
molecular surface.
(C andD) Details of the IL-3:IL3Ra interface for the open (C) and the closed (D) IL-3 binary complexmodels, showing site 1a (lower) and site 1b (upper) interactions.
Residues in IL-3 are highlighted in bold italics with putative hydrogen bonds or salt bridges displayed as black dashed lines.
(legend continued on next page)
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The two major isoforms of IL3Ra are full-length (SP1) and a
truncated isoform called SP2 that lacks the NTD (Chen et al.,
2009) that by itself has no measurable IL-3 binding (Table S5).
We measured the binding of IL-3 to IL3Ra mutants by flow
cytometry to assess IL3Ra site 1 interactions and identified res-
idues that contribute to IL-3 binding, including Q37, Y58, Q69,
F70, G71, A72, S74, A143, Q177, F198, V200, S202, N232,
E275, R276, and Y278 (Figure 3E; see the Supplemental
Results). SPR analysis revealed that mutation of Y58, G71,
E275, and Y278 abolished measurable IL-3 binding (KD >
5,000 nM) whereas mutation of Q37, Q69, Q177, F198, V200,
S202, and N232 reduced IL-3 binding as did mutation of an
adjacent residue A143 (Table S5), confirming a role for these res-
idues in IL-3 binding. All IL3Ra site 1 mutants were able to bind
radioiodinated IL-3 with wild-type (WT) affinity when coex-
pressed on cells with bc (Table S5) consistent with previous
studies where reduced ligand binding by the a receptor can be
compensated by the presence of bc (Mirza et al., 2010). Despite
the overlap of the CSL362 and IL-3 contact surfaces in the IL3Ra
NTD, only residue Y58 contributes to both interactions (Tables
S3 and S5; Figure S4B). The interactions are otherwise qualita-
tively and functionally distinct (see the Supplemental Results;
Figures S4C–S4F).
CSL362 Blocks Signaling by Preventing the Assembly of
a Higher-Order IL-3 Receptor Complex
The open conformation of IL3Ra may allow simultaneous
binding of CSL362 and IL-3 (Figure 3B) and suggested that
CSL362 may block receptor function through a mechanism in-
dependent of cytokine binding. We used our structure of the
GM-CSF ternary complex and cytokine-receptor docking to
construct IL-3 ternary complex models (see the Supplemental
Results; Figures S5A–S5D). Modeling of the open IL-3 receptor
hexamer complex suggested that CSL362 binding will not
compete for IL-3 binding in cis but will clash with IL-3 and
IL3Ra in trans through the hexamer partner (Figures S5E–
S5H), preventing dodecamer complex formation and IL-3
signaling. To test this prediction, we engineered open-like
IL3Ra mutants by substitution of IL3Ra D196 with residues
that fill the pocket between the NTD and D2 (Figure 4A). These
mutants are expected to function with properties similar to
the IL3Ra SP2 isoform, which lacks the NTD (Chen et al.,
2009). When coexpressed with bc on COS cells, we observed
comparable and moderate IL-3 binding affinities for D196L,
D196K, or D196R (D196L/D196K/D196R) IL3Ra open-like vari-
ants and IL3Ra SP2 (Figure 4B). The binding of CSL362 to the
IL3Ra D196 mutants was unchanged (Figure 4B). CSL362
effectively blocked IL-3 binding to COS cells coexpressing bc
and WT IL3Ra but only partially blocked IL-3 binding to cells
expressing the IL3Ra D196L/D196K/D196R variants and was
unable to block IL-3 binding to cells expressing IL3Ra SP2
(Figure 4C). In binding experiments using Eu-labeled IL-3 and
Tb-labeled CSL362, only COS cells expressing the IL3Ra(E) Mapping of the IL-3-binding site by Ala or EC mutation of IL3Ra site 1 residu
Relative IL-3 binding, normalized for protein expression using 9F5 (A) or 107
squares), 25%–49% (red squares), and 0%–24% (maroon squares). Data are s
Table S4 and S5.D196L/D196K/D196R variants were able to bind both ligands
simultaneously (Figure 4D). The results are consistent with the
IL3Ra D196L/D196K/D196R variants adopting an open-like
conformation that allows concomitant binding of CSL362 and
IL-3 (Figure 3B).
Ba/F3 cells coexpressing bc and the IL3Ra variants prolifer-
ated in response to IL-3 stimulation with potencies consistent
with their IL-3 binding affinities (Figure 4E). Preincubation with
CSL362 completely inhibited IL-3-mediated proliferation of Ba/
F3 cells expressing all forms of full-length IL3Ra (Figure 4F).
CSL362 also blocked IL-3-stimulated STAT5 phosphorylation
in Ba/F3 cells expressing WT, D196A, or D196K IL3Ra, but not
in cells expressing IL3Ra SP2 (Figure 4G). The observation that
CSL362 fully blocks IL-3 signaling despite only partially
competing for IL-3 binding to IL3Ra open-like mutants supports
a mechanism of action where CSL362 is able to prevent the for-
mation of a higher-order IL-3 receptor complex and is consistent
with IL-3 utilizing a dodecameric signaling complex (Figure 5).
DISCUSSION
We report here the structure of the human IL-3 receptor in com-
plex with a Fab fragment of the neutralizing mAb CSL362, which
reveals features of signaling in the type I cytokine receptor super-
family as well as a dual mechanism of antibody-mediated cyto-
kine receptor blockade (Figure 5). The structure of the IL-3
receptor showed two alternative conformations, an open and a
closed form based on the orientation of the NTD (Figure 1).
This was unexpected as the open conformation has not been
seen in the related IL-5 (Patino et al., 2011; Kusano et al.,
2012) or IL-13 receptors (LaPorte et al., 2008; Lupardus et al.,
2010). Most type I cytokine receptors include a single CRM con-
sisting of two domains with a conserved topology that forms the
main surface used to recognize ligand. The a subunits of the bc
family, IL13Ra1 and IL13Ra2, represent a group of type I recep-
tors that include an additional NTD, but the exact function of this
domain has not been clearly understood.
In the closed conformation of IL3Ra, the orientation and over-
all topology of the NTD is very similar to the NTDs of IL5Ra and
IL13Ra1/IL13Ra2 bound to ligand (Figures 1B and 1C). Our re-
sults suggest that the IL3RaNTD is highly flexible and potentially
allows subtlemodulation of ligand binding, receptor interactions,
and signaling. It is likely that the open and closed conformations
represent the dynamic extremes of NTD movement and may
also occur in the structurally related GM-CSF, IL-5, and IL-13 a
subunits.
Elucidation of the IL3Ra structure allowed us to investigate
how mAb CSL362 blocks IL-3 signaling and the role of the
NTD in this process. Epitope-mapping experiments identified
E51, S59, and R84 and to a lesser extent D49, Y58, P61, and
P88 in the NTD as important residues for CSL362 binding (Fig-
ures 2E and S4C–S4F; Table S3). To examine if the CSL362
epitope overlapped with the IL-3 binding site, we constructedes and measuring IL-3 binding by flow cytometry.
D2 (B) binding, is reported as 75%–100% (open squares), 50%–74% (pink
hown from a representative experiment (n = 3). See also Figures S3–S5 and
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Figure 4. Open-like IL3Ra Mutants Disso-
ciate CSL362 Inhibition of IL-3 Binding from
Inhibition of Signaling
(A) Close-up view of the IL3Ra NTD and D2 inter-
face in the open conformation for the WT (upper
panel) and modeled D196K mutant (lower panel).
(B) Binding affinity of IL3Ra variants for IL-3,
CSL362, or 9F5, measured in saturation binding
studies on transfected COS cells. N.B., no binding.
(C) Competition for IL-3 binding to COS cells ex-
pressing bc and IL3RaWT (filled blue circles), SP2
(open blue circles), D196A (filled black circles),
D196L (filled purple squares), D196K (filled red
squares), or D196R (filled black squares), using
labeled IL-3 at the KD value for each receptor
(from B).
(D) Directly measuring IL-3 binding and simulta-
neous CSL362 binding to COS cells expressing bc
and IL3RaWT (filled and open blue circles), D196A
(filled and open black circles), D196L (filled and
open purple squares), or D196K (filled and open red
squares) using Eu-IL-3 (filled symbols) at the KD
value for each receptor and Tb-CSL362 (open
symbols).
(E) Ba/F3 cells expressing bc and the same IL3Ra
species in (C) were stimulated with IL-3 and cell
proliferation determined.
(F) As for (E), but cells were preincubated with
CSL362 followed by IL-3 stimulation at the relevant
EC50 value (from E).
(G) As for (F), but cells were preincubated with
CSL362, stimulated with IL-3 10 min, and lysates
immunoblotted for phosphorylated STAT5 or actin.
For (C), (D), (E), and (F), the data are the mean of
triplicate determinations from a representative
experiment (n = 2) and errors represent SD. See
also Figure S5.two models of the IL3 receptor binary complex: one for each of
the observed IL3Ra conformations (Figures 3A, 3C, and 3D).
The closed IL-3:IL3Ra model (Figure 3A) is analogous to the
IL-5:IL5Ra, IL-13:IL13Ra1, and IL-13:IL13Ra2 crystal com-
plexes (Figures 1C, 1D, and S4A). A previous IL-3:IL3Ra model,
containing only D2 and D3 of IL3Ra (Dey et al., 2009), and our
current IL-3:IL3Ra models guided extensive mutagenesis of
IL3Ra and testing for IL-3 binding and signaling. Consistent
with the cytokine receptor paradigm, site 1a in IL3Ra utilizes res-
idues in the D2-D3 elbowwith F198, N232, E275, and Y278 being
major binding determinants, whereas site 1b in the NTD involved
residues Q37, Y58, Q69, and G71 (Figure 3). Importantly, many
of the IL3Ra site 1 residues identified from our IL-3:IL3Ramodels
(Figure 3; Table S4) interact with residues in IL-3 that we have416 Cell Reports 8, 410–419, July 24, 2014 ª2014 The Authorspreviously shown to be functionally impor-
tant, including S17, D21, T25, R108, F113,
K116, and E119 (Barry et al., 1994; Bagley
et al., 1996).
Although there is a small functional
overlap between the CSL362 and IL-3 epi-
topes in the IL3Ra NTD, we showed that
CSL362 binding and IL-3 function could
be dissociated (Figure S4). These resultssuggested that the overlap between the CSL362 and IL-3 epi-
topes is not sufficient to fully explain the blocking effect of
CSL362. A newmechanism of action for CSL362 was suggested
by modeling the IL-3 receptor ternary complex based on the
structure of the related GM-CSF receptor complex (Hansen
et al., 2008). We previously showed that the functional GM-
CSF receptor complex is a dodecamer formed by the associa-
tion of two hexamers, each containing a bc homodimer with
two molecules of ligand and a subunit in a head-to-head config-
uration (Hansen et al., 2008). This arrangement creates site 4 be-
tween hexamers, which can be disturbed by specific antibodies
(Hansen et al., 2008; Broxmeyer et al., 2012), and brings bc-
associated JAK2 molecules into close proximity to allow recep-
tor transphosphorylation and signaling (Figure 5). Based on the
Figure 5. Model of IL-3 Receptor Signaling and Mechanisms of Action of CSL362
(A) Binding of IL-3 to IL3Ra initiates the sequential assembly of the IL-3 receptor into an active signaling complex (dodecamer) through multiple interaction sites.
IL3Ra in yellow, IL-3 in blue, the bc homodimer in green and purple, and bc-associated JAK2 in red. Red arrows show interaction sites.
(B) CSL362 binding to closed IL3Ra prevents IL-3 binding to site 1. CSL362 Fab is shown in the blue ribbon.
(C) CSL362 binding to open IL3Ra allows IL-3 binding and hexamer formation but prevents assembly of high-order complexes.
See also Figure S5.GM-CSF ternary crystal structure, both Patino et al. (2011) and
Kusano et al. (2012) demonstrated that IL-5 could form analo-
gous higher-order structures. Our modeling studies indicate
that the IL-3 receptor complex can form similar higher-order
structures (i.e., hexamers and dodecamers) for both open and
closed IL3Ra conformations (Figure S5). Significantly, CSL362
binding to open IL3Ra in these models does not block IL-3 bind-
ing or formation of the open hexamer complex (Figures S5E and
S5F) but prevents formation of the open dodecamer complex
(Figures S5G and S5H).
Residues in the NTD-D2 interface determine the NTD orienta-
tion, and through mutagenesis of the S74 (NTD)-interacting res-
idue D196 (D2), we generated IL3Ra mutants that are predictedto adopt an open-like conformation. We showed that cells ex-
pressing these mutants bind and respond to IL-3 (Figures 4B
and 4E), but IL-3 binding is only partly competed for by
CSL362 (Figures 4C and 4D), whereas functional responses to
IL-3 are fully competed (Figures 4F and 4G). Mutation of the anal-
ogous interacting residues in IL5Ra, D208 or I69 (Figure 1E), re-
sults in drastically reduced cytokine binding, suggesting that
these residues are critical in maintaining the optimal orientation
of the NTD for cytokine binding (Patino et al., 2011). The results
support a model of IL-3 receptor activation in which IL3Ra binds
IL-3 to form a binary complex through site 1 before recruiting bc
through sites 2 and 3 to form a hexameric complex. The recruit-
ment of a second hexamer through sites 4, 5, and 6 (Lopez et al.,Cell Reports 8, 410–419, July 24, 2014 ª2014 The Authors 417
2010; Broughton et al., 2012) forms a dodecameric complex
that allows full IL-3 receptor signaling (Figure 5A). This model
illustrates the classic mechanism of antibody blockade with
CSL362 binding to closed IL3Ra and preventing ligand binding
(Figure 5B). The model also highlights a mechanism of antibody
blockade whereby CSL362 prevents the formation of the
signaling-competent open IL3Ra dodecameric complex (Fig-
ure 5C). This model is likely to apply to other members of the
bc family and to other cytokine receptor families that exhibit an
analogous NTD and highlights a way by which mAbs can exert
a ‘‘dual hit’’ to block cytokine receptor signaling.
EXPERIMENTAL PROCEDURES
Generation of Expression Constructs Encoding Full-Length IL3Ra
Mutants or Chimeras
Human IL3Ra and GMRa cDNAs were cloned into the pcDNA3.1 expression
vector (Invitrogen) and mutations generated by PCR. Selected IL3Ramutants
were cloned in the pSG5 vector (Stratagene) or the pRufPuro:bc-IRES-IL3Ra
retroviral expression vector or generated as soluble IL3Ra proteins with a
C-terminal 6xHis tag (sIL3Ra-6His). Human bc cDNA was cloned in the
pSG5 and pRufPuro:bc-IRES-IL3Ra vectors (details are provided in the Sup-
plemental Experimental Procedures).
Cell-Surface Receptor Binding and Expression Assays
Freestyle 293 suspension cells (Invitrogen) were transfected with plasmid DNA
using 293Fectin (Invitrogen) (details are provided in the Supplemental Experi-
mental Procedures). Transfected cells were stained with mAbs 7G3, 9F5 (Sun
et al., 1996), and 107D2 (Beckman Coulter Genomics) or with biotinylated
human IL-3 (ProSpec-Tany) followed by Streptavidin-PE (BD Biosciences).
Functional studies used mAb 7G3 or its humanized variant, mAb CSL362, as
they have indistinguishable specificity. mAb 9F5 binds IL3Ra NTD and mAb
107D2 binds IL3Ra D2D3 and were used as controls.
COS cells were electroporated with plasmids encoding IL3Ra alone or in the
presence of pSG5H:bc and saturation binding assays with radioiodinated anti-
body or IL-3 performed (Woodcock et al., 1996). IL-3, 9F5, and CSL362 were
radioiodinated with Pierce Pre-Coated Iodination tubes (Thermo Scientific).
Dissociation constants were calculated using EBDA and LIGAND programs
(Munson and Rodbard, 1980; KELL Radlig, Biosoft). Europium-labeled IL-3
(Eu-IL-3) and terbium-labeled CSL362 (Tb-CSL362) were prepared by DELFIA
Systems (PerkinElmer) and used in binding assays as above with cell-bound
ligand measured at 615 nm or 545 nm, respectively, using a Victor X5 multi-
plate reader (PerkinElmer; details are provided in the Supplemental Experi-
mental Procedures).
Surface Plasmon Resonance Binding Assays with sIL3Ra
The binding of IL-3, CSL362, and 9F5 to sIL3Rawasmeasured using a Biacore
4000 biosensor with a CM-5 sensor chip at 25C (details are provided in the
Supplemental Experimental Procedures).
Functional Studies for the IL-3 Receptor
Ba/F3 cell lines expressing bc and WT or D196 mutant IL3Ra were generated
using pRufPuro:bc-IRES-IL3Ra plasmids (details are provided in the Supple-
mental Experimental Procedures). Cell proliferation assays were performed
as previously described (Hansen et al., 2008). For biochemical studies, cells
were preincubated with CSL362 for 30 min prior to stimulation with IL-3 for
10 min. Cell lysates were immunoblotted with antibodies specific for phos-
phorylated STAT5 (Cell Signaling Technology) or actin as a loading control
(Millipore).
Modeling of the IL3R Binary and Ternary Complexes
The two IL-3 binary complex models (Figure 3) were constructed using the
protein-protein docking algorithm RosettaDock (Lyskov and Gray, 2008).
The two distinct IL3Ra crystal structure conformations and a human IL-3
NMR structure (PDB ID: 1JLI model 1; Feng et al., 1996) were aligned via Ca418 Cell Reports 8, 410–419, July 24, 2014 ª2014 The Authorsatoms with D3 of GMRa and GM-CSF, respectively, in the GM-CSF ternary
complex crystal structure (PDB ID: 3CXE) to produce the rough protein-protein
complexes as input to RosettaDock. We used a similar procedure to construct
IL-3:IL3Ra:bc models, which were used to generate hexamer and dodecamer
IL-3 receptor complexes (Figure S5; details are provided in the Supplemental
Experimental Procedures).
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The crystal structure has been deposited to the PDB under accession
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